• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

COVID-19 risk perception and vaccine acceptance in individuals with self-reported chronic respiratory or autoimmune conditions
COVID-19 disproportionately affects those with preexisting conditions, but little research has determined whether those with chronic diseases view the pandemic itself differently - and whether there are differ...
Source: Allergy, Asthma and Clinical Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Brianna A. Smith, Emily E. Ricotta, Jennifer L. Kwan and Nicholas G. Evans Tags: Research Source Type: research

Nanoparticle with mRNA appears to prevent, treat peanut allergies in mice
Key takeawaysPeanuts are one of the most common food allergens for children.UCLA scientists have developed a nanoparticle that delivers mRNA to liver cells in order to teach the immune system to tolerate peanut protein and alleviate allergies.In mice, the nanoparticle successfully dampened symptoms of serious allergy.Peanut allergies affect 1 in 50 children, and the most severe cases lead to a potentially deadly immune reaction called anaphylactic shock.Currently, there is only one approved treatment that reduces the severity of the allergic reaction, and it takes months to kick in. A group of UCLA immunologists is aiming ...
Source: UCLA Newsroom: Health Sciences - April 3, 2023 Category: Universities & Medical Training Source Type: news

Subacute Onset of Chronic Urticaria Post COVID-19 Vaccination
Urticaria has been known to be triggered for a variety of allergy and non-allergic etiologies. Autoimmune disease, infection, and immunizations can be considered as possible underlying differentials for non-allergic urticarial eruption. I hypothesized that a subacute onset of chronic urticarial eruptions and/or demographic state was also possibly attributable to COVID-19 vaccinations in select patients observed at a single allergy and immunology practice.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Kristy Semenza Source Type: research

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines
Conclusion: Type IIb autoimmunity seems to play a role in immediate type HSRs to the CoronaVac vaccine as previously shown in autoimmune CSU and multidrug hypersensitivity.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - February 3, 2022 Category: Allergy & Immunology Source Type: research

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol
Introduction The Global Platform for the Prevention of Autoimmune Diabetes-SINT1A Study is designed as a randomised, placebo-controlled, double-blind, multicentre, multinational, primary prevention study aiming to assess whether daily administration of Bifidobacterium infantis from age 7 days to 6 weeks until age 12 months to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in childhood. Methods and analysis Infants aged 7 days to 6 weeks from Germany, Poland, Belgium, UK and Sweden are eligible for study participation if they have a >10.0% expected ri...
Source: BMJ Open - November 9, 2021 Category: General Medicine Authors: Ziegler, A.-G., Arnolds, S., Kölln, A., Achenbach, P., Berner, R., Bonifacio, E., Casteels, K., Elding Larsson, H., Gündert, M., Hasford, J., Kordonouri, O., Lundgren, M., Oltarzewski, M., Pekalski, M. L., Pfirrmann, M., Snape, M. D., Szyp Tags: Open access, Diabetes and Endocrinology Source Type: research

BCG vaccine ’s off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot?
Allergy is an exaggerated immune response to foreign antigens resulting from a combination of genetic, epigenetic and environmental interactions. Immune responses misdirected against intrinsic antigens can lead to autoimmunity. The incidence of allergic and autoimmune diseases is rising, constituting a global public health challenge with broad socioeconomic implications. The Bacille Calmette-Gu érin (BCG) vaccine is a live attenuated Mycobacterium bovis vaccine given to millions of newborns worldwide to prevent tuberculosis.
Source: Journal of Allergy and Clinical Immunology - October 18, 2021 Category: Allergy & Immunology Authors: Asimenia Angelidou, Laure F. Pittet, Denise Faustman, Nigel Curtis, Ofer Levy Tags: Paradigms and perspectives Source Type: research

BCG vaccine ’s off-target effects on allergic, inflammatory and autoimmune diseases: Worth another shot?
Source: Journal of Allergy and Clinical Immunology - October 18, 2021 Category: Allergy & Immunology Authors: Asimenia Angelidou, Laure F. Pittet, Denise Faustman, Nigel Curtis, Ofer Levy Source Type: research

We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?
At my animal hospital in upstate New York, an epicenter of the U.S. tick epidemic, my dog Fawn lets out a whimper as the veterinarian injects her with her annual Lyme disease shot. I roll my eyes. She doesn’t know how good she has it. The injection means that if a tick bites her (and in rural New York, a tick always does), the creepy crawly will feast on dog blood that’s been supercharged with a Lyme bacteria-killing substance, and Lyme disease won’t be transmitted to Fawn. I wish I could be shot up with that superpower. Currently, there is no human vaccine for Lyme disease—even though more than two...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Disease feature Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who ...
Source: J Korean Med Sci - March 30, 2021 Category: General Medicine Authors: Jin Kyun Park Eun Bong Lee Kichul Shin Yoon Kyoung Sung Tae Hwan Kim Seong Ryul Kwon Myeung Su Lee Seung Jae Hong Byoong Yong Choi Shin Seok Lee Han Joo Back Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimm Source Type: research

Pages: 1  2  3  4  5  6